SANTA MONICA, Calif., Oct. 9 /PRNewswire-FirstCall/ -- Aida Pharmaceuticals, Inc. (OTC Bulletin Board: AIDA), one of mainland China's leading pharmaceutical companies, today announced that the Chinese government has loosened national restrictions for the sale of Etimicin sulfate throughout China. Aida expects the sales of the Company's main revenue-generating product to increase noticeably as sales efforts are pursued nationwide without restriction.
The Ministry of Labor and Social Security eliminated restrictions on Etimicin, which is in the aminoglycoside antibiotic family. Aminoglycoside antibiotis were previously thought to be potentially unsafe for treating patients with a history of kidney disease. Although Etimicin had been clinically established to be safe and effective for people with such issues, it was not until now that the restrictions have been lifted.
Jin Biao, Chairman and CEO of Aida Pharmaceuticals, noted, "This is strong substantiation by the appropriate governmental regulatory body that the safeness of Etimicin has been universally and officially recognized. We are definitely pleased at this acceptance of the outstanding characteristic of low toxicity in this new generation of aminoglycoside antibiotics. We believe that this will allow us to promote the sales of Etimicin and broaden our customer base."
For more information about the lifting of the restriction for this particular type of drug please visit: http://www.molss.gov.cn/gb/ywzn/2007-06/20/content_183083.htm
About Etimicin Sulfate
Etimicin Sulfate is a new generation of the aminoglycoside family of
antibiotics. Developed by Aida and its research partners, it is the first
antibiotic developed in China. Aida has the exclusive right to the
production and marketing of this powder and infusion type and is protected
by patent through 2013. Etimicin sulfate is a semi-syn
|SOURCE Aida Pharmaceuticals|
Copyright©2007 PR Newswire.
All rights reserved